Amphastar Pharmaceuticals reported its third-quarter 2025 results, revealing quarterly revenues of US$191.84 million and net income of US$17.35 million, with sales of Baqsimi and Primatene Mist ...

Amphastar Pharmaceuticals' third quarter results for 2025 came in ahead of Wall Street's revenue and profit expectations, despite essentially flat sales compared to the prior year. The quarter was ...

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) achieved net revenues of $191.8 million for the third quarter, with a GAAP net income of $17.3 million. The company's core products, Bexsemi and Primatene ...

Amphastar Pharmaceuticals Inc ((AMPH)) has held its Q3 earnings call. Read on for the main highlights of the call. Amphastar Pharmaceuticals’ recent earnings call revealed a resilient performance, ...

An attempt to protect the ozone layer has effectively removed the only over-the-counter asthma inhaler from the market, forcing some asthma sufferers to find room in their budgets for visits to the ...

You don't need to spend a lot of money or go on a cooking course to prepare pasta that looks like it came straight out of a restaurant. Sometimes the secret lies in a simple touch, an ingredient that ...

Hanmi Pharmaceutical signed an agreement last Tuesday with Boehringer Ingelheim Korea to distribute and promote three chronic obstructive pulmonary disease (COPD) treatments nationwide: Spiriva ...